AU2021361731A1 - Compositions and methods for storage stable ophthalmic drugs - Google Patents
Compositions and methods for storage stable ophthalmic drugs Download PDFInfo
- Publication number
- AU2021361731A1 AU2021361731A1 AU2021361731A AU2021361731A AU2021361731A1 AU 2021361731 A1 AU2021361731 A1 AU 2021361731A1 AU 2021361731 A AU2021361731 A AU 2021361731A AU 2021361731 A AU2021361731 A AU 2021361731A AU 2021361731 A1 AU2021361731 A1 AU 2021361731A1
- Authority
- AU
- Australia
- Prior art keywords
- aceclidine
- concentration
- container
- degrees celsius
- viscosity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/069,155 US11273150B2 (en) | 2018-10-10 | 2020-10-13 | Compositions and methods for the treatment of presbyopia |
US17/069,155 | 2020-10-13 | ||
PCT/US2021/029536 WO2022081204A1 (en) | 2020-10-13 | 2021-04-28 | Compositions and methods for storage stable ophthalmic drugs |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2021361731A1 true AU2021361731A1 (en) | 2023-05-25 |
Family
ID=81209258
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2021361731A Pending AU2021361731A1 (en) | 2020-10-13 | 2021-04-28 | Compositions and methods for storage stable ophthalmic drugs |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP4228636A1 (ko) |
JP (1) | JP2023544918A (ko) |
KR (1) | KR20230131822A (ko) |
CN (1) | CN116847841A (ko) |
AU (1) | AU2021361731A1 (ko) |
CA (1) | CA3195422A1 (ko) |
MX (1) | MX2023004298A (ko) |
WO (1) | WO2022081204A1 (ko) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA100393C2 (ru) * | 2007-10-16 | 2012-12-25 | Сан Фарма Адвансед Ресьорч Компані Лімітед | Новые офтальмологические композиции |
US20190038609A1 (en) * | 2013-08-28 | 2019-02-07 | Presbyopia Therapies, LLC | Compositions and methods for the treatment of presbyopia |
MX2017016517A (es) * | 2015-06-18 | 2018-05-28 | Presbyopia Therapies Llc | Composiciones estables al almacenamiento y metodos para el tratamiento de errores de refraccion del ojo. |
MA53873A (fr) * | 2018-10-10 | 2022-01-19 | Presbyopia Therapies Inc | Compositions et procédés pour le traitement de la presbytie |
-
2021
- 2021-04-28 EP EP21880707.1A patent/EP4228636A1/en active Pending
- 2021-04-28 MX MX2023004298A patent/MX2023004298A/es unknown
- 2021-04-28 CA CA3195422A patent/CA3195422A1/en active Pending
- 2021-04-28 KR KR1020237016074A patent/KR20230131822A/ko active Search and Examination
- 2021-04-28 CN CN202180081410.1A patent/CN116847841A/zh active Pending
- 2021-04-28 AU AU2021361731A patent/AU2021361731A1/en active Pending
- 2021-04-28 JP JP2023547174A patent/JP2023544918A/ja active Pending
- 2021-04-28 WO PCT/US2021/029536 patent/WO2022081204A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
CN116847841A (zh) | 2023-10-03 |
KR20230131822A (ko) | 2023-09-14 |
CA3195422A1 (en) | 2022-04-21 |
WO2022081204A1 (en) | 2022-04-21 |
MX2023004298A (es) | 2023-08-09 |
EP4228636A1 (en) | 2023-08-23 |
JP2023544918A (ja) | 2023-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10836760B2 (en) | Compositions and methods for the treatment of presbyopia | |
US20190038609A1 (en) | Compositions and methods for the treatment of presbyopia | |
US10307408B2 (en) | Contact lens compositions and methods for the treatment of presbyopia | |
WO2017160548A1 (en) | Compositions and methods for the treatment of presbyopia | |
US10052313B2 (en) | Compositions and methods for the treatment of presbyopia | |
US20230414494A1 (en) | Compositions and methods for the treatment of presbyopia | |
US10959990B2 (en) | Compositions and methods for the treatment of presbyopia | |
US20220233434A1 (en) | Compositions and methods for the treatment of presbyopia | |
US10617763B2 (en) | Compositions and methods for the treatment of presbyopia | |
US20190240152A1 (en) | Contact lens compositions and methods for the treatment of presbyopia | |
US20230414587A1 (en) | Compositions and methods for storage stable ophthalmic drugs | |
US20180235946A1 (en) | Compositions and methods for the treatment of presbyopia | |
US11273150B2 (en) | Compositions and methods for the treatment of presbyopia | |
AU2021361731A1 (en) | Compositions and methods for storage stable ophthalmic drugs | |
US20230398064A1 (en) | Compositions and methods for the treatment of presbyopia | |
US11648247B1 (en) | Compositions and methods for the treatment of presbyopia | |
US20230310392A1 (en) | Compositions and methods for the treatment of eye conditions | |
WO2019135927A1 (en) | Contact lens compositions and methods for the treatment of presbyopia | |
WO2023114347A9 (en) | Compositions and methods for the treatment of eye conditions | |
BR122022017130B1 (pt) | Composições e métodos para o tratamento da presbiopia |